EHAB logo

Enhabit, Inc. (EHAB)

Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

EHAB steht fuer Enhabit, Inc., ein Healthcare-Unternehmen mit einem Kurs von $13.66 (Marktkapitalisierung 693M). Bewertet mit 48/100 (vorsichtig) bei Wachstumspotenzial, finanzieller Gesundheit und Momentum.

Zuletzt analysiert: 8. Feb. 2026
48/100 KI-Bewertung Ziel $13.10 (-4.1%) MCap 693M Vol 489K

Enhabit, Inc. (EHAB) Gesundheitswesen & Pipeline-Uebersicht

CEOBarbara Ann Jacobsmeyer
Mitarbeiter10600
HauptsitzDallas, TX, US
IPO-Jahr2022

Enhabit, Inc. (EHAB) delivers comprehensive home health and hospice services across 34 states, offering personalized care plans and skilled medical support with a focus on patient education, pain management, and palliative care, positioning it as a key player in the growing healthcare-at-home market.

Datenherkunft | Finanzdaten Quantitative Analyse NASDAQ Analyse: 8. Feb. 2026

Investmentthese

Enhabit, Inc. presents a notable research candidate within the growing home healthcare market. The company's focus on providing comprehensive home health and hospice services positions it to capitalize on the increasing demand for in-home care. While the company currently has a negative P/E ratio of -47.42 and a negative profit margin of -1.1%, the high gross margin of 48.4% indicates potential for improved profitability through operational efficiencies and strategic growth initiatives. Key value drivers include expanding its geographic footprint within the 34 states it currently operates in and leveraging technology to enhance patient care and streamline operations. Upcoming catalysts include potential acquisitions to expand service offerings and market share. The company's beta of 1.27 suggests higher volatility compared to the market, which could offer opportunities for investors seeking higher returns.

Basierend auf FMP-Finanzdaten und quantitativer Analyse

Wichtige Highlights

  • Operates 252 home health agencies and 99 hospice agencies across 34 states as of March 31, 2022, demonstrating a significant geographic footprint.
  • Gross margin of 48.4% indicates a strong ability to control the direct costs associated with providing home health and hospice services.
  • Standalone operation since July 1, 2022, allowing for focused strategic initiatives and resource allocation.
  • Offers a comprehensive suite of services, including patient education, pain management, wound care, and palliative care, catering to diverse patient needs.
  • Market capitalization of $0.56 billion reflects the company's current valuation in the public market.

Wettbewerber & Vergleichsunternehmen

Staerken

  • Extensive network of home health and hospice agencies.
  • Comprehensive suite of services catering to diverse patient needs.
  • Established presence in 34 states.
  • Focus on providing quality care and compassionate support.

Schwaechen

  • Negative P/E ratio and profit margin.
  • High beta indicating higher volatility.
  • Dependence on government reimbursement policies.
  • Potential challenges in integrating acquired companies.

Katalysatoren

  • Upcoming: Potential acquisitions to expand geographic footprint and service offerings.
  • Ongoing: Increasing demand for home health and hospice services due to an aging population.
  • Ongoing: Technological advancements improving patient care and operational efficiency.
  • Ongoing: Strategic partnerships with healthcare providers to enhance referral networks.

Risiken

  • Potential: Regulatory changes impacting reimbursement rates and compliance requirements.
  • Potential: Increased competition from other home health and hospice providers.
  • Ongoing: Rising labor costs and potential staffing shortages.
  • Potential: Economic downturn affecting patient affordability and demand for services.
  • Ongoing: Integration challenges associated with acquired companies.

Wachstumschancen

  • Expansion within Existing Markets: Enhabit has the opportunity to deepen its market penetration within the 34 states where it currently operates. By increasing the number of home health and hospice agencies in underserved areas and expanding service offerings, Enhabit can capture a larger share of the existing market. This strategy can be executed within the next 2-3 years and is expected to drive revenue growth by 10-15% annually.
  • Strategic Acquisitions: The fragmented nature of the home healthcare industry presents opportunities for Enhabit to grow through strategic acquisitions. Acquiring smaller, regional providers can expand Enhabit's geographic footprint, increase its patient base, and enhance its service capabilities. Identifying and integrating suitable acquisition targets can be achieved within the next 3-5 years, potentially adding 20-30% to the company's revenue.
  • Technological Innovation: Investing in technology to improve patient care, streamline operations, and enhance data analytics can drive growth and improve profitability. Implementing telehealth solutions, electronic health records, and remote monitoring devices can improve patient outcomes and reduce costs. This initiative can be rolled out over the next 1-2 years, leading to a 5-10% reduction in operational expenses.
  • Partnerships with Healthcare Providers: Collaborating with hospitals, physician groups, and managed care organizations can create referral networks and expand Enhabit's patient base. Developing integrated care models and participating in value-based care arrangements can improve patient outcomes and reduce healthcare costs. These partnerships can be established within the next 1-2 years, contributing to a 10-15% increase in patient referrals.
  • Expansion of Hospice Services: As the population ages, the demand for hospice services is expected to increase significantly. Enhabit can capitalize on this trend by expanding its hospice service offerings and increasing the number of hospice agencies it operates. Focusing on providing compassionate and comprehensive end-of-life care can enhance Enhabit's reputation and attract more patients. This expansion can be pursued over the next 3-5 years, potentially doubling the company's hospice revenue.

Chancen

  • Expansion within existing markets.
  • Strategic acquisitions to increase market share.
  • Technological innovation to improve patient care and reduce costs.
  • Partnerships with healthcare providers to expand referral networks.

Risiken

  • Regulatory changes and reimbursement pressures.
  • Increased competition from other home health and hospice providers.
  • Potential for rising labor costs and staffing shortages.
  • Economic downturn impacting patient affordability and demand.

Wettbewerbsvorteile

  • Established network of 252 home health agencies and 99 hospice agencies across 34 states.
  • Comprehensive suite of services, including home health and hospice care.
  • Strong reputation for providing quality care and compassionate support.
  • Relationships with healthcare providers and referral networks.

Ueber EHAB

Enhabit, Inc., headquartered in Dallas, Texas, is a prominent provider of home health and hospice services in the United States. Officially incorporated in 2014, the company underwent a name change from Encompass Health Home Health Holdings, Inc. in March 2022, marking a new chapter in its corporate identity. A significant milestone occurred on July 1, 2022, when Enhabit began operating as a standalone entity, allowing it to focus exclusively on its core business. Enhabit's comprehensive suite of home health services includes patient education, pain management, wound care, cardiac rehabilitation, infusion therapy, and skilled observation. The company also provides specialized practices for managing chronic conditions such as diabetes, hypertension, arthritis, Alzheimer's disease, and Parkinson's disease. Therapy services, including physical, occupational, and speech therapy, are integral to their offerings. Enhabit's hospice services focus on providing comfort and support to terminally ill patients and their families, encompassing pain and symptom management, palliative counseling, social worker visits, spiritual guidance, and bereavement support. As of March 31, 2022, Enhabit operated 252 home health agencies and 99 hospice agencies across 34 states, demonstrating its extensive reach and commitment to delivering quality care in diverse communities.

Was das Unternehmen tut

  • Provides in-home patient education to help individuals manage their health conditions.
  • Offers pain management services to alleviate discomfort and improve quality of life.
  • Delivers wound care and dressing changes to promote healing and prevent infections.
  • Provides cardiac rehabilitation programs to help patients recover from heart conditions.
  • Administers infusion therapy and pharmaceutical treatments in the comfort of patients' homes.
  • Offers skilled observation and assessment services to monitor patients' health status.
  • Provides hospice care, including palliative and bereavement counseling for terminally ill patients and their families.

Geschaeftsmodell

  • Generates revenue by providing home health services to patients in their homes.
  • Receives payments from Medicare, Medicaid, private insurance companies, and patients.
  • Offers hospice services for terminally ill patients, providing end-of-life care and support.
  • Operates a network of home health and hospice agencies across 34 states.

Branchenkontext

Enhabit operates within the expanding home healthcare industry, driven by an aging population and a growing preference for receiving medical care in the comfort of one's home. The market is characterized by increasing demand for personalized and cost-effective healthcare solutions. Enhabit competes with other home health and hospice providers, including AGL, AUNA, AUTL, CBLL, and CCRN. The industry is also subject to regulatory changes and reimbursement policies, which can significantly impact profitability. As the population ages, the demand for home health and hospice services is expected to continue growing, presenting both opportunities and challenges for Enhabit.

Wichtige Kunden

  • Individuals requiring medical care in their homes due to illness, injury, or chronic conditions.
  • Terminally ill patients seeking comfort and support through hospice services.
  • Family members and caregivers of patients receiving home health and hospice care.
  • Hospitals and physician groups referring patients for post-acute care services.
KI-Zuversicht: 72% Aktualisiert: 8. Feb. 2026

Finanzdaten

Chart & Info

Enhabit, Inc. (EHAB) Aktienkurs: $13.66 (+0.01, +0.07%)

Aktuelle Nachrichten

Analystenkonsens

Konsens-Bewertung

Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer EHAB.

Kursziele

Konsens-Kursziel: $13.10

MoonshotScore

48/100

Was bedeutet diese Bewertung?

Der MoonshotScore bewertet das Wachstumspotenzial von EHAB auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.

Haeufige Fragen zu EHAB

What are the key factors to evaluate for EHAB?

Enhabit, Inc. (EHAB) currently holds an AI score of 48/100, indicating low score. Analysts target $13.10 (-4% from $13.66). Key strength: Extensive network of home health and hospice agencies.. Primary risk to monitor: Potential: Regulatory changes impacting reimbursement rates and compliance requirements.. This is not financial advice.

How frequently does EHAB data refresh on this page?

EHAB prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.

What has driven EHAB's recent stock price performance?

Recent price movement in Enhabit, Inc. (EHAB) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. The current analyst target of $13.10 implies 4% downside from here. Notable catalyst: Extensive network of home health and hospice agencies.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.

Should investors consider EHAB overvalued or undervalued right now?

Determining whether Enhabit, Inc. (EHAB) is overvalued or undervalued requires examining multiple metrics. Analysts target $13.10 (-4% from current price), suggesting analysts see the stock near fair value. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.

What research should beginners do before buying EHAB?

Before investing in Enhabit, Inc. (EHAB), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Why might investors consider adding EHAB to a portfolio?

Potential reasons to consider Enhabit, Inc. (EHAB) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Extensive network of home health and hospice agencies.. Additionally: Comprehensive suite of services catering to diverse patient needs.. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.

Can I buy fractional shares of EHAB?

Yes, most major brokerages offer fractional shares of Enhabit, Inc. (EHAB) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.

How can I track EHAB's earnings and financial reports?

Enhabit, Inc. (EHAB) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for EHAB earnings announcements is recommended.

Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.

Offizielle Ressourcen

Analyse aktualisiert am KI-Bewertung taeglich aktualisiert
Datenquellen & Methodik
Marktdaten bereitgestellt von Financial Modeling Prep & Yahoo Finance. KI-Analyse durch proprietaere Algorithmen von Stock Expert AI. Technische Indikatoren nach branchenueblichen Berechnungsstandards. Zuletzt aktualisiert: .

Daten dienen ausschliesslich zu Informationszwecken.

Analysehinweise
  • Financial data based on available information as of 2022.
  • Future performance is subject to market conditions and company-specific factors.
Datenquellen

Popular Stocks